eScholarship
metadata only
Target Identification and Validation of the Imidazolopiperazine Class of Antimalarials
The antimalarial resistance arms race is alive and well. In 2022, the Plasmodium genus of parasites were responsible for 249 million cases of malaria, 608,000 of which were fatal (WHO, 2023). This increase in cases is attributed to lack of an effective vaccine and restricted access to preventative a
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."#1150174
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar#1307874
- A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria#1184238
- Efficacy of pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs for malaria control in Benin: a cluster-randomised, superiority trial#328623
- Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax#869261
Record · ID 1235088
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive